Skip to main content
. 2021 Nov 27;22(23):12840. doi: 10.3390/ijms222312840

Figure 7.

Figure 7

MAN1A1, EPB41, HSD17B13 and MYOM2 are altered in prostate cancer patients. (A,B) Ualcan analysis in prostate adenocarcinoma identified (A) 4 target genes (MAN1A1, EPB41, HSD17B13 and MYOM2) with increased promoter methylation in primary prostate cancer tumors (n = 502) compared to normal prostatic samples (n = 50) and (B) MAN1A1 RNA expression in metastatic prostate cancer (PC) (n = 42) vs. non-metastatic prostate cancer (n = 44). (C) cBioportal analysis of relationship between MYOM2 expression and progression free survival. * = significantly different between conditions.